Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: Clinical presentation, diagnosis, management and emerging therapies

Ilia G. Halatchev, Jingsheng Zheng, Jiafu Ou

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Cardiac amyloidosis is thought to be a rare group of diseases caused by extracellular deposition of misfolded proteins in the extracellular cardiac matrix resulting in heart failure with preserved ejection fraction (HFpEF). This review focuses on the similarities and differences between the pathophysiology, clinical presentation and diagnostic tests of wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) compared to immunoglobulin light chain amyloidosis and hereditary cardiac amyloidosis. We address some obstacles to timely diagnosis and opportunities for management of the clinical symptoms as well as possibility of future novel disease modifying therapies.

Original languageEnglish
Pages (from-to)2034-2045
Number of pages12
JournalJournal of Thoracic Disease
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2018

Keywords

  • ATTRwt cardiac amyloidosis (ATTRwt-CA)
  • Heart failure with preserved ejection fraction (HFpEF)
  • Left ventricular hypertrophy (LVH)
  • Senile amyloidosis
  • Transthyretin

Fingerprint

Dive into the research topics of 'Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: Clinical presentation, diagnosis, management and emerging therapies'. Together they form a unique fingerprint.

Cite this